<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03781544</url>
  </required_header>
  <id_info>
    <org_study_id>OPIOVASC</org_study_id>
    <nct_id>NCT03781544</nct_id>
  </id_info>
  <brief_title>Effects of Opioids and NSAIDs on Sympathetic Nervous System and Vascular Function</brief_title>
  <acronym>OPIOVASC</acronym>
  <official_title>Effect of Opioids and NSAIDs on Sympathetic Nervous System and Vascular Function in Healthy Subjects and Patients With Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the effect of different analgesic treatments (Tramadol, Paracetamol,&#xD;
      Diclofenac) on sympathetic nerve activity, blood pressure, heart rate, heart rate, and&#xD;
      vascular function in osteoarthritis patients and healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hundreds of millions of patients worldwide require pain-relieving therapy to maintain an&#xD;
      acceptable quality of life. Pain relievers, including non-steroidal anti-inflammatory drugs&#xD;
      (NSAIDs) and opioids, however, exert unwanted potent adverse systemic off-target effects and&#xD;
      their use is associated with a well-documented excess of cerebrovascular and cardiovascular&#xD;
      events. This of particular concern for the one fourth of the world's population aged over 35&#xD;
      years suffering from chronic pain, particularly with arthritis of whom half also present with&#xD;
      established or at high risk of cardiovascular disease. This uncertainty around the&#xD;
      cardiovascular safety of pain relieving drugs leaves practitioners and their patients with&#xD;
      difficult management decisions and underscores the need to investigate potential differential&#xD;
      cardiovascular effects of NSAIDs and opioids and to better delineate the underlying&#xD;
      mechanisms involved. Indeed, currently available NSAIDs invariably disrupt the balance&#xD;
      between prostacyclin and thromboxane, but may also exert multiple and opposing cardiovascular&#xD;
      effects on endothelial factors, including nitric oxide and reactive oxygen species, the&#xD;
      sympathetic nervous system and vascular inflammation. Intriguingly, the net effect of pain&#xD;
      relieving drugs on vascular function and sympathetic nerve activity and its resulting&#xD;
      deterioration of blood pressure control is increasingly recognized as a major possible&#xD;
      determinant in explaining the cardiovascular side effects of NSAIDs. As a result of the&#xD;
      ongoing concerns around the cardiovascular safety of NSAIDs and coxibs many patients are&#xD;
      being withheld effective pain relieve or switched to opioids and/or paracetamol under the&#xD;
      assumption of their yet unproven greater cardiovascular safety. The absence of evidence about&#xD;
      the cardiovascular safety of these drugs presents a major dilemma for patients and&#xD;
      physicians, who have been warned about the toxicity of NSAIDs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>resting MSNA (sympathetic nervous activity )</measure>
    <time_frame>1day (110 min)</time_frame>
    <description>Effect of different single analgesic treatments (Tramadol, Paracetamol, Diclofenac) on resting muscle sympathetic nerve activity (MSNA) in osteoarthritis patients (post 2 days of analgesic therapy washout phase) and in healthy subjects.&#xD;
Tramadol treatment will be compared to diclofenac and paracetamol (3 treatment arms).&#xD;
90 participants (45 osteoarthritis patients, 45 healthy subjects);&#xD;
Single infusion of Tramadol (50 mg i.v.) Single infusion of Paracetamol (1000 mg i.v.) Single infusion of Diclofenac (75 mg i.v.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>changes in FMD (Flow mediated vasodilation)</measure>
    <time_frame>1 day (210min)</time_frame>
    <description>Effect of a single acute intravenous analgesic treatment with tramadol versus paracetamol on changes in flow mediated dilatation (FMD) in osteoarthritis patients and in healthy subjects.&#xD;
Tramadol treatment will be compared with paracetamol as we previously demonstrated that paracetamol exerts no significant effects on endothelial function as measured by flow mediated dilatation.&#xD;
80 participants (40 osteoarthritis patients, 40 healthy subjects);&#xD;
Single infusion of Tramadol (50 mg i.v.) Single infusion of Paracetamol (1000 mg i.v.)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Osteoarthritis of Multiple Joints of Ankle or Foot</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Diclofenac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diclofenac (Diclofenacum natricum) A single i.v. infusion of Diclofenac (dose: 75mg/100ml) will be administered to the participants (treatment arm).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paracetamol (Paracetamol Sintetica):&#xD;
A single i.v. infusion of Paracetamol (dose: 1g/100ml) will be administered to the participants (control arm).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tramadol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tramadol (Tramadol-Mepha):&#xD;
A single i.v. infusion of Tramadol (dose: 400mg/100ml) will be administered to the participants (treatment arm).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol</intervention_name>
    <description>A single i.v. infusion of Tramadol (dose: 400mg/100ml) will be administered to the participants (treatment arm).</description>
    <arm_group_label>Tramadol</arm_group_label>
    <other_name>Tramadol-Mepha</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>A single i.v. infusion of Paracetamol (dose: 1g/100ml) will be administered to the participants (control arm).</description>
    <arm_group_label>Paracetamol</arm_group_label>
    <other_name>PARACETAMOL Sintetica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac</intervention_name>
    <description>A single i.v. infusion of Diclofenac (dose: 75mg/100ml) will be administered to the participants (treatment arm).</description>
    <arm_group_label>Diclofenac</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients ≥ 18 years of age, male or female, with a diagnosis of osteoarthritis or&#xD;
             healthy subjects ≥ 18 years of age;&#xD;
&#xD;
          2. Written informed consent;&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. History of hypersensitivity or allergy to any of the study drugs&#xD;
&#xD;
          2. Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or other&#xD;
             major CV surgery, percutaneous coronary intervention (PCI) or carotid angioplasty&#xD;
             within the 3 months prior to Visit 1;&#xD;
&#xD;
          3. Coronary or carotid artery disease likely to require surgical or percutaneous&#xD;
             intervention within the 3 months after Visit 1;&#xD;
&#xD;
          4. Presence of significant endocrine diseases;&#xD;
&#xD;
          5. Presence of active acute infectious diseases;&#xD;
&#xD;
          6. Known narrow-angle glaucoma;&#xD;
&#xD;
          7. Known epilepsy;&#xD;
&#xD;
          8. Cimino-shunt operation on both arms;&#xD;
&#xD;
          9. Pregnancy, intention thereof during study, lack of sufficient contraception,&#xD;
             breastfeeding;&#xD;
&#xD;
         10. Drug or alcohol abuse;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Ruschitzka, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cardiology, University Heart Center Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabella Sudano, MD</last_name>
    <phone>+41442555841</phone>
    <email>Isabella.Sudano@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne-Marieke Vegter</last_name>
    <phone>+41442552280</phone>
    <email>Anne-Marieke.Vegter@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Heart Center Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Ruschitzka, MD</last_name>
      <phone>+41442553353</phone>
      <email>frank.ruschitzka@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 3, 2018</study_first_submitted>
  <study_first_submitted_qc>December 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2018</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

